[HTML][HTML] Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
[HTML][HTML] Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
AS Wong, R Soong, SBK Seah, SW Lim… - Journal of Thoracic …, 2008 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer chemotherapy and …, 2010 - Springer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
[HTML][HTML] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib
Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
Phase II study of erlotinib in advanced non–small-cell lung cancer after failure of gefitinib
BC Cho, CK Im, MS Park, SK Kim, J Chang… - Journal of clinical …, 2007 - ascopubs.org
Purpose This study was designed to evaluate the efficacy and toxicity of erlotinib in patients
with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression …
with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression …
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
ZT Zhou, XH Xu, Q Wei, M Lu, J Wang… - Cancer chemotherapy and …, 2009 - Springer
Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type
F Hirai, M Edagawa, S Shimamatsu… - Oncology …, 2017 - spandidos-publications.com
Erlotinib is one of the treatment choices for patients with advanced non‑small cell lung
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection
A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa… - Lung cancer, 2011 - Elsevier
BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …